Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution and Shedding of Talimogene Laherparepvec in Melanoma
NCT02014441Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2014
- Primary completion
- Jan 2016
- Modality
- Oncolytic Viruses
- Countries
- 2
01
Overview
A Phase 2 trial of talimogene laherparepvec in melanoma, sponsored by Amgen. Started Apr 2014; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02014441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014441.